|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients显示文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal. | Markus Moehler Martin F Sprinzl Murad Abdelfattah Carl C Schimanski Bernd Adami Werner Godderz Klaus Majer Dimitri Flieger Andreas Teufel Juergen Siebler Thomas Hoehler Peter R Galle Stephan Kanzler | 2009 | World Journal of Gastroenterology2009，15，4： | 10 |
| 2 | Rodent neonatal bilateral carotid artery occlusion with hypoxia mimics human hypoxic ischemic injury显示文摘 | Recker R Adami A Tone B | 2009 | J Cereb Blood Flow Metab2009，29，： | 1 |
| 3 | The p21CDK-interacting protein Gip1 is a potent inhibitor of G1cyclin-dependent kinases显示文摘 | Adami G R Wei N | 1993 | Cell1993，75，： | 1 |
| 4 | Adigital broadband beamforming architecture for 2 - PAD显示文摘 | ARMSTRONG R HICKISH J ZARB ADAMI K | | P h y sic s0，13，3： | 1 |
| 5 | Determination of the geographical origin of Brazilian wines by isotope and mineral analysis显示文摘 | Durra S V Adami L Marcon A R | 2011 | Analytical and Bioanalytical Chemistry2011，401，5： | 1 |
| 6 | Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization显示文摘 | Amano S Rohan R Kuroki M Tolentino M Adamis AP | 1998 | Invest Ophthalmol Vis Sci1998，39，1： | 1 |
| 7 | Optimal performance and delocalization in NK fitness landscapes显示文摘 | Campos P R A Adami C Wilke C O | 2002 | Physica A2002，304，34： | 1 |
| 8 | The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases显示文摘 | Harper J W Adami G R Wei N | 1993 | Cell1993，75，4： | 1 |
| 9 | State-of-the-art and trends in scalable video compression with waveletbased approaches显示文摘 | ADAMI N SIGNORONI A LEONARDI R | 2007 | IEEE Transactions on Circuits and Systems for Video Technology2007，17，9： | 1 |
| 10 | MK 801 and de-xamethasone reduce both tumor necrosis factor levels and infarct volume after focal cerbral ischemia in the rat brain 显示文摘 | Bertorelli R Adami M Di S E | 1998 | Neurosoi Let1998，246，1： | 1 |
| 11 | Study of the solubility of iron in zirconium by thermoelectric power measurements显示文摘 | BORRELLY R MERLE P ADAMI L | 1990 | J Nuel Mater1990，170，： | 1 |
| 12 | Nanomaterials and supercritical fluids 显示文摘 | Reverchon E Adami R | 2006 | Journal of Supercritical Fluids2006，37，： | 1 |
| 13 | Pigment Red 60 micronization using supereritical fluids based techniques显示文摘 | REVERCHON E ADAMI R MARCO I De | 2005 | The Journal of Supercritical Fluids2005，35，1： | 1 |
| 14 | Effect of age,weight and lifestyle factors on calcaneal quantitative ultrasound in premenopausal women,the ESOPO study显示文摘 | Adami S Giannini S Giorgino R | | 0，，04： | 1 |
| 15 | Reduction criterion for separability显示文摘 | Cerf N J Adami C Gingrich R M | 1999 | Phys Rev A1999，60，： | 1 |
| 16 | On Synchronization Techniques: Performance and Impact on Time Metrics Monitoring 显示文摘 | ADAMI D GARROPPO R G GIORDANO S | 2003 | International Journal of Communication Systems2003，，16： | 1 |
| 17 | Supercritical AntiSolvent micronization of nalmefene HCI on laboratory and pilot scale 显示文摘 | Adami R Reverchon E | 2007 | Powder Technology2007，179，： | 1 |
| 18 | Peptidemediated gene delivery:influence of peptide structure on gene expression 显示文摘 | WADHWA M S COLLARD W T ADAMI R C | 1997 | Bioconjug Chem1997，8，1： | 1 |
| 19 | Risk of cancer in women receiving hormone replacement therapy 显示文摘 | Adami HO Persson I Hoover R | 1989 | Int J Cancer1989，44，5： | 1 |
| 20 | Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization显示文摘 | Amano S Rohan R Kuroki M Tolentino M Adamis AP | 1998 | Invest Ophthalmol Vis Sci1998，39，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员